



# Società Italiana di Tossicologia

- La Società Italiana di Tossicologia non ha fini di lucro, politici e sindacali ed ha durata illimitata, ha come logo il nome "SITOX" e sede amministrativa a Milano

## Presidente

Corrado L. Galli

## Past Presidente

Patrizia Hrelia

## Presidente Eletto

Orazio Cantoni

## Consiglio Direttivo

Francesca Maffei

Guido Mannaioli

Angelo Moretto

Michele Navarra

Emanuela Testai

Sarah Vecchio

Barbara Viviani

- I principali obiettivi della SITOX sono indirizzati a:

- promuovere la ricerca scientifica nei diversi ambiti della Tossicologia;
- stimolare il confronto e rapporti di collaborazione con Istituzioni nazionali e internazionali, Enti di ricerca ed altre Organizzazioni scientifiche responsabili per la tutela della salute e dell'ambiente;
- diffondere l'informazione tossicologica nell'opinione pubblica attraverso comunicati, eventi e conferenze;
- promuovere la formazione e l'aggiornamento dei tossicologi attraverso congressi, convegni, seminari e corsi ECM;
- riconoscere, attraverso l'istituzione del Registro Nazionale dei Tossicologi Certificati (RENTIC) la figura del tossicologo certificato.



# Società Italiana di Tossicologia

## Presidente

Corrado L. Galli

## Past Presidente

Patrizia Hrelia

## Presidente Eletto

Orazio Cantoni

## Consiglio Direttivo

Francesca Maffei

Guido Mannaioni

Angelo Moretto

Michele Navarra

Emanuela Testai

Sarah Vecchio

Barbara Viviani

# SITOX

410 Soci ordinari


23 soci sostenitori

4 soci onorari

*Prof. Lewis Goldfrank,  
Prof. Pier Francesco Mannaioni,  
Prof. Rodolfo Paoletti,  
Prof. Paolo Preziosi*

**Presidente**  
Corrado L. Galli  
**Past Presidente**  
Patrizia Hrelia  
**Presidente Eletto**  
Orazio Cantoni

**Consiglio Direttivo**  
Francesca Maffei  
Guido Mannaioli  
Angelo Moretto  
Michele Navarra  
Emanuela Testai  
Sarah Vecchio  
Barbara Viviani



## DISTRIBUZIONE DEI 410 SOCI SITOX IN BASE ALLA REGIONE SEDE DELL'ISTITUZIONE DI AFFERENZA

**Presidente**

Corrado L. Galli

**Past Presidente**

Patrizia Hrelia

**Presidente Eletto**

Orazio Cantoni

**Consiglio Direttivo**

Francesca Maffei

Guido Mannai


Angelo Moretto

Michele Navarra

Emanuela Testai

Sarah Vecchio

Barbara Viviani



**distribuzione dei soci ordinari in base al settore professionale di afferenza**



UNIVERSITÀ DEGLI STUDI DI MILANO  
DIPARTIMENTO DI SCIENZE  
FARMACOLOGICHE E BIOMOLECOLARI

## INTRODUZIONE ALL'ANALISI DEL RISCHIO IN CAMPO ALIMENTARE

CORRADO LODOVICO GALLI - ERT


Contaminazione da inquinanti organici persistenti nella catena alimentare:  
monitoraggio, ricerca e caratterizzazione del rischio

Aula Magna Campus Mattei, Località Crocicchia, 61029 Urbino (PU)

# SIMPLE QUESTIONS versus DIFFICULT ANSWERS



What chemical(s)  
are we **exposed to?**



**At what dose is  
toxicity observed**



- Where do they cause toxicity?
- What are the mechanism of toxicity?
- Who is susceptible?



# ENSURING THE SAFETY OF CHEMICALS

---

- ❖ Synthetic
- ❖ Persistent
- ❖ Natural
- ❖ Endocrine active



# PUBLIC HEALTH and RISK ANALYSIS



# RISK ASSESSMENT

- ① Assess the intrinsic **hazard** of a chemical and establish a level of safety;
- ② Determine the level of **exposure** to a chemical;
- ③ Compare the daily intake (*exposure*) with the *health based guidance values (HBGVs)* to ensure that the **risk is acceptable** in light of all the existing scientific evidence.



# HAZARD



Hazard is the potential capacity of producing harm.



# RISK



Risk is proportional to both the hazard and the extent of exposure.



# REFERENCE POINTS - POINTS OF DEPARTURE

Toxicants or  
Non DNA reactive-Carcinogens

- ◆ No-Observed-(Adverse)-Effect-Level (NO(A)EL)
- ◆ Benchmark Dose (BMD)


DNA reactive-  
Carcinogens

- ◆ Benchmark Rose (BMR)
- ◆ TR25
- ◆ TR50




# ANIMAL-BASED TOXICOLOGICAL STUDIES

(QUANTIFICATION OF ADVERSE HEALTH EFFECTS)



# HEALTH BASED GUIDANCE VALUES (HBGVs)



# ADMISSIBLE DAILY INTAKE



$$\text{ADI} = \frac{\text{NOAEL/BMD}}{\text{SF}}$$



**ADI** = Admissible Daily Intake mg/kg b.w.


**NOAEL** = No Observed Adverse Effect Level (mg/kg b.w.)

**BMD** = Benchmark Dose (mg/kg b.w.)

**SF** = Safety Factor (10, 100, n)




# PESTICIDES HEALTH BASED GUIDANCE VALUES



# PESTICIDES CONSUMERS RISK ASSESSMENT



# HEALTH BASED GUIDANCE VALUES (HBGVs)



# MARGIN OF EXPOSURE (MoE)

$$\text{MoE} = \frac{\text{NOAEL/BMD}}{\text{EXPOSURE}}$$

NOAEL/BMD  25 mg/kg b.w.

EXPOSURE  0.0005 mg/kg/day

■ MoE = > 10,000




# ENSURING THE SAFETY OF CHEMICALS

---

- ❖ Synthetic
- ❖ Persistent
- ❖ Natural
- ❖ Endocrine active



# CUMULATIVE EFFECT




## Bioaccumulation:

refers to the accumulation of substances, of a chemicals in an organism.



# CUMULATIVE EFFECT




## Biomagnification:


increase in concentration of a pollutant from one link in a food chain to another



# CUMULATIVE EXPOSURE



# AGGREGATE EXPOSURE



## POLYCHLORINATED DIBENZO-P-DIOXINS/DIBENZOFURANS (PCDD/FS\*) POLYCHLORINATED BIPHENYLS (PCB)

- Polychlorinated Dibenzo-p-Dioxins (PCDD) (75)
- Polychlorinated Dibenzofurans (PCDF) (135)
- (17/210)
  
- Non-Dioxin-like polychlorinated biphenyls (NDL-PCB) (197)
- Dioxin-like polychlorinated biphenyls (DL-PCBs/DL-PCBs) (12)
- (12/209)
  
- 17 PCDD/Fs are relatively persistent in animals and humans and therefore considered relevant.
- \*Considered non-genotoxic carcinogens, bioaccumulative, with very large kinetic differences between animals and humans



<b>CONGENER</b>	<b>relative effect potency (REP)</b> WHO <sub>2005</sub> - TEF	<b>pg</b>	<b>total toxic equivalent (TEQ)</b> WHO <sub>2005</sub> - TEF	<b>pg/kg bw</b>
<b>PCDD</b>				
2,3,7,8 - TCDD	1	20	20	0.29
1,2,3,7,8 - PeCDD	1	60	60	0.86
1,2,3,4,7,8 - HxCDD	0.1	10	1	0.014
1,2,3,6,7,8 - HxCDD	0.1	70	7	0.1
1,2,3,4,6,7,8 - HpCDD	0.01	130	1.3	0.02
1,2,3,4,6,7,8,9 - OCDD	0.0003	600	0.2	0.003
<b>Total</b>		<b>890</b>	<b>89.5</b>	<b>1.3</b>



# METALS

- Metals can neither be created nor destroyed
  - Problematic environmental contaminants
  - However, chemical form of the metal can be altered
- Metals are naturally occurring
  - Natural sources of toxicity
  - Anthropogenic activities increase metal toxicity either because:
    - Metals are moved from biologically inaccessible to accessible compartments in the biosphere.
    - Form of the metal is changed to more bioavailable or toxic form



# MERCURY (Hg)

## ❖ Elemental

- ❖ liquid at room temperature that volatizes readily
- ❖ rapid distribution in body by vapor, poor in GI tract

## ❖ Inorganic

- ❖ poorly absorbed in GI tract, but can be caustic
- ❖ dermal exposure has resulted in toxicity

## ❖ Organic

- ❖ lipid soluble and well absorbed via GI, lungs and skin
- ❖ can cross placenta, BBB and into breast milk



# MERCURY (Hg)

- ❖ Toxicity occurs with long term exposure and effects the CNS.
    - ❖ Signs progress from paresthesias to ataxia, followed by generalized weakness, visual and hearing impairment, tremor and muscle spasticity, and then coma and death.
  - ❖ Teratogen with large chronic exposure
    - ❖ Asymptomatic mothers with severely affected infants
    - ❖ Infants appeared normal at birth, but psychomotor retardation, blindness, deafness, and seizures developed over time.
- ❖ NOAEL: 1.5 mg/kg b.w./day



# ARSENIC (As)

- ❖ As <sup>III</sup>:
  - ❖ bind to sulphydryl groups leading to inhibition of enzymatic systems
  - ❖ inhibit the Krebs cycle and oxidative phosphorylation. These lead to inhibition of ATP production
- ❖ As <sup>V</sup>
  - ❖ can replace the stable phosphate ester bond in ATP and produce an arsenic ester stable bond which is not a high energy bond
- ❖ BMDL<sub>10</sub> :0.0003 mg/kg b.w./day



# LEAD (Pb)

- ❖ Lead has affinity for SH groups and is toxic to zinc-dependent enzyme systems
  - ❖ Heme synthesis: hemoglobin, cytochromes
  - ❖ Steroid metabolism and membrane integrity
  - ❖ Interference in vitamin D synthesis in renal tubular cells  
(conversion of 1-hydroxyvitamin D to 1,25-hydroxyvitamin D)
    - ❖ **BMDL<sub>10</sub>: 0.00063 mg/kg b.w./day**



# ENSURING THE SAFETY OF CHEMICALS

---

- ❖ Synthetic
- ❖ Persistent
- ❖ **Natural**
- ❖ Endocrine active



# SOSTANZE TOSSICHE NEGLI ALIMENTI

## NATURALI

- Normali componenti degli alimenti (nutrienti)
  
- NATURALI CONTAMINANTI DEGLI ALIMENTI
  - TOSSINE NATURALI
  
  - Contaminazione di origine microbiologica
  - Tossine presenti negli alimenti animali



# MICOTOSSINE



# TOSSICITA' MICOTOSSINE

EPATOTOSSINE	CANCEROGENE	NEFROTOSSINE	TERATOGENE	MUTAGENE
Aflatossine	Patulina	Ocratossine	Aflatossina	Aflatossine
Rubratossine	Ac. Penicillico	Aflatossine	Rubratossine	Patulina
Sporidesmina	Aflatossine	Citrinina	Tricoteceni	Ac. Penicillico
Ocratossine	Tricoteceni		Ocratossine	Rubratossina



# MYCOTOXINS

- Aflatoxin B<sub>1</sub> <10 ppb (food)
- Aflatoxin M<sub>1</sub> <0.5 ppb (milk)
- Patulin 0.4 µg/kg bw (PMTDI)
- Fumosin B<sub>1</sub> 2.0 µg/kg bw (PMTDI)
- Deoxynivalenol 1.0 µg/kg bw (PMTDI)
- T-2 and HT-2toxin 60 ng/kg bw (PMTDI)
- Ochratoxin A 100 ng/kg bw (**PTWI**)



# ENSURING THE SAFETY OF CHEMICALS

---

- ❖ Synthetic
- ❖ Natural
- ❖ Persistent
- ❖ Endocrine active



# CRITERIA FOR ENDOCRINE DISRUPTION

COMMISSION REGULATION (EU) 2018/605 OF 19<sup>TH</sup> APRIL 2018

An **active substance** shall be considered as having endocrine disruption properties that may cause adverse effect in humans if, it is a substance that meets all of the following criteria, unless there is evidence demonstrating that the adverse effect identified are **not relevant to humans**:

1. It shows an adverse effect in **an intact organism** or its progeny, which is a change in the morphology, physiology, growth, development, reproduction or life span of an organism, system or (sub)population that results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress or an increase in susceptibility to other influences;
2. It has an endocrine mode of action, i.e. it alters the function(s) of the endocrine system;
3. The adverse effect is a consequence of the endocrine mode of action



# RISK ANALYSIS

